Fig. 4: CBD decreases IL-12-related toxicity of armoured CAR-T cells.
Male C57BL6/J mice received subcutaneous injection of RM9-hSTEAP1 (5 × 105) on day 0. CAR-T cells were intravenously administered on day 4. a, Serum ALT and b, ALP concentrations on day 12 (each dot represents a mouse, mean ± s.e.m.). c–e, Immunohistochemistry quantification of CD3+ T cell infiltration in liver (c), lung (d) and kidney (e) on day 14 (each dot represents a mouse, mean ± s.e.m.). Statistical analyses were performed using Kruskal–Wallis test followed by Dunn’s multiple comparisons (non-parametric data) (a,e) or one-way ANOVA with Tukey’s test (b–d). P values are shown in figures.
